6.51
-0.50 (-7.07%)
| Previous Close | 7.00 |
| Open | 6.49 |
| Volume | 2,536,946 |
| Avg. Volume (3M) | 4,285,933 |
| Market Cap | 1,046,290,240 |
| Price / Sales | 1.56 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 - 12 May 2025 |
| Profit Margin | -27.49% |
| Operating Margin (TTM) | -142.09% |
| Diluted EPS (TTM) | -1.23 |
| Quarterly Revenue Growth (YOY) | -69.70% |
| Quarterly Earnings Growth (YOY) | 179.90% |
| Current Ratio (MRQ) | 0.980 |
| Operating Cash Flow (TTM) | -87.26 M |
| Levered Free Cash Flow (TTM) | -175.64 M |
| Return on Assets (TTM) | -8.63% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Novavax, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.50 |
|
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 8.80% |
| % Held by Institutions | 60.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Shah Capital Management | 31 Dec 2024 | 11,148,846 |
| Sanofi | 31 Dec 2024 | 6,880,481 |
| Tsp Capital Management Group, Llc | 31 Dec 2024 | 1,358,565 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 31 Mar 2025 | CNBC | Vaccine stocks fall after key FDA official resigns in protest of RFK Jr. |
| 11 Mar 2025 | Announcement | Novavax Announces Changes to Board of Directors |
| 27 Feb 2025 | Announcement | Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights |
| 27 Feb 2025 | Announcement | Novavax to Participate in Upcoming March Investor Conferences |
| 20 Feb 2025 | Announcement | Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025 |
| 04 Feb 2025 | CNBC | Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary |
| 23 Jan 2025 | Announcement | Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc. |
| 13 Jan 2025 | CNBC | Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |